ASC Ordered to Produce Patient Billing Records by Florida Appeals Court

By John Freund |

Sand Lake Surgery Center was ordered to produce billing records for two patients. A Florida appeals court made the ruling despite Sand Lake selling its stake in the case to American Medical Funding.

Please log in to view membership only content
Log In Register

Commercial

View All

Summary of the Lords’ Committee Stage Debate on the Litigation Funding Bill

By John Freund |

Following the second debate of the Litigation Funding Agreements (Enforceability) Bill in the House of Lords, the bill was moved forward to the committee stage for members to propose amendments and undertake a line by line examination. As LFJ reported yesterday, three amendments were proposed in advance of the committee debate, with two being put forward by Lord Stewart of Direlton, the Advocate-General of Scotland, and one by Lord Marks of Henley-on-Thames. 

LFJ has read through the full transcript of the committee stage debate and has provided a summary, highlighting key takeaways from the contributions made by each of the members of the House.

Yesterday’s debate was opened by Lord Stewart, who began by responding to issues raised by other members during the second reading of the bill. With regards to the retrospective nature of the bill, Lord Stewart acknowledged the potential issues that this could raise for claimants who negotiated new funding arrangements post-PACCAR, and told the House that “the Government are looking into the questions raised and hope to provide a further update on Report.” 

Lord Stewart then went on to introduce the two amendments on behalf of the government, starting with Amendment 1 which was described as a “technical amendment” and was designed to close a small gap in the definition of litigation funding agreements (LFAs). He explained that the amendment would ensure that an LFA “which is used to fund items of expenditure where the litigant is unrepresented” will be rendered enforceable by the new legislation. He stated that this amendment “reflects the policy object of the Bill”, and would avoid any LFAs being missed in the government’s efforts to reverse the impact of the PACCAR ruling.

Amendment 2 was also described as another technical change, which Lord Stewart said would “make it clear that the payment of adverse costs the litigant may be required to pay to another party, which would be funded under an LFA, includes the payment of costs following court, tribunal or arbitration proceedings, or as part of a settlement.”

Following on from Lord Stewart’s introduction of the government’s amendments, Lord Marks began by covering the arguments in favour of the introduction of regulation for the litigation funding market. Among these arguments, the most prominent point raised by Lord Marks was the idea that “in an unregulated market, litigation funders can effectively impose their terms on clients”, thereby reducing the amount of compensation that claimants may receive from any settlement. He also pointed to the question posed by others that, “if regulation of DBAs is appropriate for lawyers, why is it not for litigation funders?”

Lord Marks then continued on to address the issue of “retrospectivity” in the bill, noting that concerns had been raised that the retrospective nature of the bill and that any legislation attempting to include such a measure, must demonstrate “special justification”. Lord Marks said that he had concluded that in order to avoid “confusion and uncertainty”, this was one such situation that demonstrated special justification because it would ensure  that “in the case of LFAs between the PACCAR decision and the commencement of this Bill, such LFAs should be in the same position as LFAs entered into in the interregnum or in the interim period.”

Moving on to his own probing amendment, which called for a review into third-party funding and laid out the scope of the proposed review’s focus, Lord Marks acknowledged that “it has been comprehensively and well answered” both by letters from the Secretary of State and Lord Stewart, and by the publishing of the terms of reference for the Civil Justice Council (CJC) review. He went on to say that he was “pleased to see that the Government realise that this is urgent and that the whole question of looking at the field of litigation funding is both important and urgent.”

Speaking briefly about the CJC’s planned review, Lord Marks expressed that he was pleased to see the breadth of the review’s remit, including the issue of “whether there should be regulation and how, if there is to be regulation , it should be framed.” Among the other important issues that the review will be exploring, Lord Marks highlighted areas including the idea of a cap on funder’s returns, the recoverability of funder’s costs, and the potential conflicts of interest between funders, law firms and their clients.

Lord Marks closed his contribution by voicing his support for both of the government’s amendments.

Lord Carlile of Berriew was the next member of the House to speak, addressing the questions previously raised around the bill’s potential to violate the Human Rights Act and whether the retrospective quality of the bill. Lord Carlile spoke succinctly in saying that the arguments about the Human Rights Act were “not strong, and the Government are perfectly entitled to act as they are in that regard.” Furthermore, he went on to say that this legislation “would be absolutely pointless if it were not retrospective”, arguing that the purpose of the bill was to “right a wrong that nobody expected, and it is simply restoring to people the legal rights which they already had.”

Lord Carlile also took time to briefly endorse the CJC review and its terms of reference, going on to praise the choice of the CJC as the reviewing body. He explained that he would not be “an enthusiast for an independent reviewer in this situation”, and that the CJC would have the ability to be flexible whilst also retaining the ability to “change the law in small ways to ensure that appropriate procedures are followed.”

Baroness Bennett of Manor Castle followed Lord Carlile but rose to voice opposition to the current approach to this legislation and said that it “is still not an adequate solution to the problems at hand.” She argued that the government is actually facing “a structural problem”, arguing that the current legal system demonstrates a “huge inequality of arms”. She concluded by saying that under this existing system, which the bill does not attempt to deal with, “there is far too much justice denied to individuals in our society when they are crushed by the weight of corporations or the state.”

Lord Sandhurst joined Lord Carlile in supporting the government’s amendments, arguing in favour of the retrospective nature of the bill whilst this opens up the possibility of “a spate of future litigation of the wrong satellite nature”, the government cannot afford to allow the current situation to continue. Considering the issue of a challenge by the ECHR, Lord Sandhurst argued that when crafting this type of legislation, “There may be no perfect answer, but this is the right route—or the least bad.”

Lord Thomas of Cwmgiedd spoke briefly in support of the bill and the CJC review, noting that the reviewer will be able to draw upon the lessons learned during Australia’s review of litigation funding regulations and the research completed by the European Law Institute. He argued that the example of Australia may demonstrate that the best strategy is not “the creation of yet another regulatory body” but instead giving the courts “the powers and guidance necessary to deal with the issues.”

Lord Ponsonby of Shulbrede was the final peer to join the debate and took the time to address the real world use cases for litigation funding, highlighting its value to small and medium-sized companies to manage their cashflow whilst pursuing meritorious litigation. He argued that the use of LFAs is an ideal “way of managing risk”, and that the UK should not fall behind other jurisdictions such as Singapore, Australia, and Dubai, which would happily take up this share of the global litigation funding market.

Lord Stewart returned to the floor to close out the debate, taking the time to address issues and concerns raised by each of the members and reiterate the objectives of the government’s bill. Of primary importance procedurally, Lord Stewart focused on Lord Marks’ amendment requiring a review of the third-party funding sector, stating that in the face of the CJC review “his amendment is not necessary and will duplicate efforts.” Therefore, he requested that Lord Marks not press the amendment at this stage.

At the close of the debate, both of the government’s amendments were agreed and as Lord Marks had decided not to press his amendment, the debate was ended. The amended version of the bill can be read here.

The bill now moves to the report stage, which provides an opportunity for members of the Lords to further examine the bill and propose any additional amendments to the text. 

The full transcript of the committee stage debate can be read here.

Omni Bridgeway Releases Investment Portfolio Report for 3Q24

By John Freund |

Omni Bridgeway Limited (ASX: OBL) (Omni Bridgeway, OBL, Group) announces the key investment performance metrics for the three months ended 31 March 2024 (3Q24, Quarter) and for the financial year to date (FYTD).

Summary

  • Investment income of A$296 million FYTD; A$56 million provisionally attributable to OBL.
  • 23 full completions, 17 partial completions FYTD, with an overall multiple on invested capital (MOIC) of2.0x.
  • A$333 million of new commitments FYTD with a corresponding A$447 million in new fair value, on track to achieve our A$625 million target.
  • Pricing remains at improved levels, up 32% for the FYTD compared to FY23.
  • Strong pipeline, with agreed term sheets outstanding for an estimated A$212 million in new commitments.
  • OBL cash and receivables of A$101 million plus A$60 million in undrawn debt at 31 March 2024.
  • A$4.4 billion of possible estimated portfolio value (EPV) in completions over the next 12 months. 
  • Further simplification and enhancement of our disclosures as announced at the Annual General Meeting, comprising non-IFRS OBL-only financials and non-IFRS fair value on a portfolio basis and OBL-only basis.
  • These new disclosures and metrics, as well as a valuation framework for our existing book and platform, were presented at our investor day on 27 March 2024.

Refer to https://omnibridgeway.com/investors/investor-day.

Key metrics and developments for the Quarter

Income and completions

  • Investment income of A$296 million generated from A$193 million income recognised and A$103 million income yet to be recognised (IYTBR), with A$56 million provisionally attributable to OBL FYTD (excluding management and performance fees). 
  • During the Quarter, 11 full completions and 11 partial completions (excluding IYTBR), resulting in 23 full completions and 17 partial completions (excluding IYTBR) FYTD, and one secondary market transaction, with a FYTD overall MOIC of 2.0x.

New commitments

  • Our stated targets for FY24 include A$625 million in new commitments or equivalent value, prioritising value over volume to reflect potential for improved pricing of new commitments.
  • FYTD new commitments of A$333 million at 31 March 2024 (from matters that were newly funded, conditionally approved or had increased investment opportunities). 
  • The fair value associated with these commitments is $447million, 72% of the full year value generation target.
  • Pipeline of 37 agreed exclusive term sheets, representing approximately A$212 million in investment opportunities, which if converted into funded investments is a further 34% of our FY24 commitments target.  
  • In addition to the regular new commitments to investments in the existing funds FYTD, an additional A$11.5 million of external co-fundings were secured for these investments to manage fund concentration limits. OBL will be entitled to management fees as well as performance fees on such external co-funding.

Portfolio review

  • A$4.4 billion of EPV is assessed to possibly complete in the 12 months following the end of the quarter. This 12 month rolling EPV is based on investments which are subject to various stages of (anticipated) settlement discussions or for which an award or a judgment is expected. All or only part of these may actually complete during the 12 month period.
  • We anticipate replacing these final EPV metrics with fair value metrics by the end of this financial year.

Cash reporting and financial position

  • At 31 March 2024, the Group held A$100.7 million in cash and receivables (A$62.8 million in OBL balance sheet cash, A$2.0 million in OBL balance sheet receivables and A$35.9 million of OBL share of cash and receivables within Funds) plus access to a further A$60 million in debt.
  • In aggregate, we have approximately A$161 million to meet operational needs, interest payments, and fund investments before recognising any investment completions, secondary market sales, management and transaction fees, and associated fund performance fees.
  • Post Quarter-end and as per the date of this report, in anticipation of the expiry of the availability period of the debt facility, OBL has drawn down the A$60 million in undrawn debt and received the funds.

Investor day

The investor day presentation and Q&A which took place on 27 March 2024 can be viewed at https://omnibridgeway.com/investors/investor-day.

Read More

Litigation Funding Support Ensures Law Firm Can Continue MoD Lariam Claims

By Harry Moran |

A frequent talking point among claimant law firms and litigation funders is the use of delaying and prolonging tactics by defendants, hoping to continually increase the financial cost of bringing a case until it is no longer viable to do so. However, as a recent example demonstrates once again, third-party litigation funding provides a significant weapon in the claimant’s arsenal when it comes to combating this type of strategy.

An article in The Law Society Gazette covers ongoing developments in the group action being brought against the Ministry of Defence over claims that its prescription of Lariam, an anti-malarial drug, caused harmful side effects to armed forces personnel. The law firm leading these claims, Hilary Meredith Solicitors, has denied reporting that it is facing bankruptcy due to the large costs involved in the case, and told the Gazette that its financial backing is secure.

In a statement to the Gazette, the law firm stated that its “bank and litigation funders have confirmed their ongoing financial support”, which will allow the law firm to continue with the Lariam cases without fear of bankruptcy. Hilary Meredith Solicitors admitted that whilst it had been necessary “to borrow millions of pounds to fund this David and Goliath type action”, the law firm’s financial footing was secure with the support of outside lenders.

The identity of the litigation funder supporting Hilary Meredith Solicitors is not specified by the law firm’s statement or the Gazette’s reporting.

The firm also confirmed that with 10 lead cases scheduled for trial at the High Court next year, they are now “close” to agreeing a settlement with the MoD. The Gazette also cites its reporting from last year, which revealed that the MoD had spent £20 million on its legal budget to defend against the claims brought between 2021 and 2022.